Research programme: neurokinin-1 receptor antagonists - OPKO Health

Drug Profile

Research programme: neurokinin-1 receptor antagonists - OPKO Health

Alternative Names: NK-1 antagonists - Schering-Plough; OPK 88002

Latest Information Update: 11 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Developer OPKO Health
  • Class Antiemetics; Antipruritics
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pruritus
  • No development reported Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 08 May 2018 OPKO Health plans a phase IIa trial of OPK 88002 for Pruritus in 2018
  • 08 Aug 2017 OPKO Health's receives approval for an IND application for initiation of a phase IIa trial of OPK 88002 for Pruritus before August 2017
  • 09 May 2017 OPKO Health plans a phase IIa trial for Pruritus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top